Aptevo Research and Development LLC
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
Previously recorded as Emergent Product Development Seattle, LLC (to 2016)
3
Ending by 2030
May 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 4, 2026The maintenance fee for CD37 Immunotherapeutics and Uses Thereof (US 10,307,481) comes due Dec 4, 2026. Unpaid by Jun 4, 2027, it lapses early.
- 2 fees due Feb 11 to 15, 2027 · next Feb 11
- 1 fee due Sep 26, 2027The maintenance fee for CD123 Binding Proteins and Related Compositions and Methods (US 11,939,392) comes due Sep 26, 2027. Unpaid by Mar 27, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,333,966 | CD37 Immunotherapeutics and Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,101,609 | CD37 Immunotherapeutic and Combination with Bifunctional Chemotherapeutic Thereof In force · High confidence | In force | High confidence | |
| US 8,409,577 | Single-Chain Multivalent Binding Proteins with Effector Function In force · Medium confidence | In force | Medium confidence | |
| US 10,307,481 | CD37 Immunotherapeutics and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,760,116 | Prostate-Specific Membrane Antigen Binding Proteins and Related Compositions and Methods In force · High confidence | In force | High confidence | |
| US 9,745,381 | Bispecific SCFV Immunofusion (BIF) In force (reinstated) · High confidence | In force (reinstated) | High confidence | |
| US 10,676,533 | Methods of treatment of CD123 overexpressing disorders In force · Medium confidence | In force | Medium confidence | |
| US 11,242,400 | CD123 Binding Proteins and Related Compositions and Methods In force · High confidence | In force | High confidence | |
| US 11,939,392 | CD123 Binding Proteins and Related Compositions and Methods In force · High confidence | In force | High confidence | |
| US 12,441,798 | CD123 Binding Proteins and Related Compositions and Methods In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 13: 1 patent in force now held by others · 11 lapsed for an unpaid fee · 2 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
6 pending · 8 abandoned